查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1985626

癌症疼痛管理市场：2026-2032年全球市场预测（按药物类别、给药途径、分销管道、最终用户和应用划分）

Cancer Pain Management Market by Drug Class, Route Of Administration, Distribution Channel, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，癌症疼痛管理市场价值将达到 83.5 亿美元，到 2026 年将成长至 88.7 亿美元，到 2032 年将达到 129.1 亿美元，复合年增长率为 6.41%。

主要市场统计数据
基准年 2025 83.5亿美元
预计年份：2026年 88.7亿美元
预测年份 2032 129.1亿美元
复合年增长率 (%) 6.41%

这是一本权威的癌症疼痛管理入门指南，系统地说明了临床复杂性、多学科护理以及整个医疗保健系统相关人员的战略重点。

癌症疼痛管理在肿瘤学、安宁疗护和医疗保健系统经济学的交会点占据着至关重要的地位。肿瘤学的进步延长了许多患者的生存期，凸显了对细緻入微且持续的疼痛管理方法的需求日益增长，以维持患者的功能和生活品质。如今，临床医生必须平衡急性手术相关疼痛、慢性癌症相关疼痛症候群、复杂的神经病变疼痛、合併症、多重用药以及患者的多样化需求。因此，疼痛管理策略必须具有适应性、以实证医学为基础，并与不断发展的护理标准保持一致。

临床个体化、阿片类药物的合理使用、新的给药技术以及支付方主导的结果如何重塑癌症疼痛管理在各种护理路径中的应用？

目前，癌症疼痛管理正经历多项变革，这些变革正在改变临床实践和商业策略的整体方向。首先，随着疼痛亚型表型分析的改进以及对神经病变性疼痛和伤害性疼痛机制理解的加深，镇痛治疗方案正明显地向个体化方向发展。这种转变促使临床医师根据疼痛病因和患者的特定风险因子来选择治疗方法，而不是依赖统一的治疗方案。

评估 2025 年美国关税措施对癌症止痛药物的供应和取得的多方面营运和采购影响。

2025年实施的政策和贸易措施带来了新的趋势，影响癌症止痛药物的采购、定价行为和供应链规划。影响进口活性药物成分和成品製剂的关税调整，增加了製造商和医疗保健系统采购决策的复杂性。许多相关人员正在透过重新评估其供应商组合，并加快生产和原材料采购多元化策略来应对关税带来的成本压力。

透过详细的細項分析，明确产品定位、与临床路径的一致性以及按药物类别、给药途径、分销管道、使用者和应用进行分销差异化。

基于细分市场的分析揭示了不同药物类别、给药途径、分销管道、终端用户环境和特定应用需求的临床和商业性趋势差异。药物类别包括辅助镇痛药、局部麻醉剂、非类固醇消炎剂和鸦片类药物。在辅助性止痛药中，抗惊厥药、抗忧郁症和皮质类固醇等特定亚类药物针对癌症疼痛的神经性和发炎性成分；而阿片类药物则进一步分为天然、半合成和合成药物，它们具有不同的受体谱、安全性考虑因素和监管规定。

对美洲、欧洲、中东和非洲以及亚太地区的准入模式、处方实践和供应链影响进行区域分析。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的医疗服务取得模式、治疗方法选择和相关人员的优先事项均有显着影响。在美洲，综合医疗服务体系和专科药局的强大影响力正推动新型给药平台和病患支援计画的快速普及。同时，监管机构对鸦片类药物安全性的重视持续影响处方规范和合理用药工作。相较之下，欧洲、中东和非洲地区的支付方结构和采购体系则呈现出多元化的特点，部分市场存在集中式竞标系统，而当地药品目录根深蒂固，且各地区的姑息治疗基础设施也存在差异。

主要企业如何透过研发、管理方法创新、经销伙伴以及真实世界数据来满足癌症疼痛治疗中尚未满足的需求，从而实现差异化？

随着各公司寻求差异化策略以应对癌症疼痛管理中复杂的临床问题和支付方的需求，竞争格局正在改变。主要企业正将针对非鸦片类药物和辅助性治疗的标靶研究与新型给药系统的投资相结合，以优化安全性和提高用药依从性。同时，学名药和专科药物生产商也在拓展支持用药依从性的服务，例如病患教育和护理师主导的剂量调整方案，同时强调供应可靠性和成本效益。

为领导者提供可操作且优先考虑的建议，以加强供应韧性，推广遏制阿片类药物使用的治疗方法，并使商业模式与可衡量的临床结果保持一致。

产业领导者可以透过实施以下几项切实可行的建议，采取果断行动，从而获得临床认可和商业性优势。首先，应优先考虑供应链多元化和紧急生产伙伴关係，以确保产品供应稳定，同时降低贸易和原材料中断带来的风险。其次，应加速开发和推广非鸦片类疗法及辅助药物，以应对癌症疼痛的神经病变和发炎性因素，从而支持旨在减少鸦片类药物使用的临床方案。

严谨的混合方法研究框架，结合专家访谈、文献整合和真实世界资料（REW），同时确保在限制和伦理保障方面保持透明。

本分析整合了混合方法研究的成果，该方法结合了定性和定量方法，以确保可靠的检验。主要研究包括对临床医生、药房经理、医院采购负责人和保险公司代表进行结构化访谈，以了解他们对临床需求、处方集决策标准和采购趋势的第一手观点。此外，还对同行评审的临床指南、监管公告和政策分析进行了文献综述，以补充这些研究结果，从而将不断发展的标准和合理使用要求置于更广阔的背景下进行分析。

策略结论强调在临床、商业和政策领域开展合作，将创新转化为可靠的、以患者为中心的癌症疼痛治疗。

总之，癌症疼痛管理正处于策略转折点，临床创新、政策压力和供应链现实在此交汇，重新定义了止痛药的给药和评估方式。个人化治疗方案、非鸦片类药物疗法和给药技术的进步为改善病患功能和安全性提供了重要契机，但只有当相关人员就药物管理、实证实践和取得模式达成共识时，这些成果才能得以实现。不断变化的价格和采购环境进一步凸显了建立具有韧性的供应策略和合约机制以保障医疗服务连续性的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：癌症疼痛管理市场：依药物类别划分

  • 辅助止痛药
    • 抗惊厥药物
    • 抗忧郁症
    • 皮质类固醇
  • 局部麻醉剂
  • NSAIDs
  • 阿片类药物
    • 自然的
    • 半合成
    • 合成

第九章：癌症疼痛管理市场：依给药途径划分

  • 口服
    • 胶囊
    • 解决方案
    • 药片
  • 肠外
    • 肌肉内部
    • 静脉
    • 皮下
  • 舌下
    • 电影
    • 锭剂
  • 经皮

第十章：癌症疼痛管理市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十一章：癌症疼痛管理市场：以最终用户划分

  • 癌症专科医疗机构
  • 居家照护
  • 医院

第十二章 癌症疼痛管理市场：依应用领域划分

  • 骨转移引起的疼痛
  • 神经性疼痛
  • 内臟疼痛

第十三章 癌症疼痛管理市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 癌症疼痛管理市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 癌症疼痛管理市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国癌症疼痛管理市场

第十七章：中国癌症疼痛管理市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Aegis Therapeutics, LLC
  • Aptinyx Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Glaxosmithkline PLC
  • Grunenthal Group
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Scilex Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Trevena Inc.
Product Code: MRR-144C638C8F7B

The Cancer Pain Management Market was valued at USD 8.35 billion in 2025 and is projected to grow to USD 8.87 billion in 2026, with a CAGR of 6.41%, reaching USD 12.91 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.35 billion
Estimated Year [2026] USD 8.87 billion
Forecast Year [2032] USD 12.91 billion
CAGR (%) 6.41%

An authoritative introduction to cancer pain management that frames clinical complexity, multidisciplinary care, and strategic priorities for stakeholders across health systems

Cancer pain management occupies a pivotal intersection between oncology care, palliative medicine, and health system economics. Advances in oncology have extended survival for many patients, which in turn has broadened the need for nuanced, sustained approaches to pain control that preserve function and quality of life. Clinicians now balance acute procedural pain, chronic cancer-related pain syndromes, and complex neuropathic presentations alongside comorbidities, polypharmacy, and diverse patient preferences. Consequently, pain management strategies must be adaptable, evidence-driven, and aligned with evolving standards of care.

Across care settings, the imperative is to deliver targeted analgesia while minimizing adverse effects and dependence risks. This requires integration of pharmacologic options spanning adjuvant analgesics, local anesthetics, nonsteroidal anti-inflammatory drugs, and opioid therapies with nonpharmacologic modalities and interventional techniques. Regulatory frameworks, public health priorities on opioid stewardship, and payer policies are reshaping provider decision-making. Moreover, patient-centered models that incorporate shared decision-making and outcomes measurement are becoming central to defining value in therapy selection.

Given these complexities, stakeholders need consolidated, clinically rigorous guidance that synthesizes therapeutic modalities, route-of-administration considerations, distribution dynamics, and end-user requirements. This executive summary distills strategic insights and practical recommendations designed to inform clinical leaders, product strategists, and health systems as they adapt to a rapidly changing therapeutic landscape for cancer-associated pain.

How clinical personalization, opioid stewardship, new delivery technologies, and payer-driven outcomes are reshaping cancer pain management across care pathways

The landscape of cancer pain management is undergoing several transformative shifts that collectively reorient clinical practice and commercial strategy. First, there is a measurable move toward personalized analgesic regimens driven by improved phenotyping of pain subtypes and a clearer understanding of neuropathic versus nociceptive mechanisms. This shift is encouraging clinicians to select therapies based on pain etiology and patient-specific risk factors rather than a one-size-fits-all algorithm.

Simultaneously, opioid stewardship initiatives and heightened scrutiny of opioid prescribing are accelerating adoption of multimodal approaches that emphasize adjuvant analgesics, regional techniques, and targeted non-opioid pharmacotherapies. These changes are compounded by the emergence of novel delivery platforms and transdermal systems that improve adherence and minimize systemic exposure. Digital therapeutics, remote monitoring, and telemedicine are further altering care pathways by enabling continuous assessment of pain, side effects, and patient-reported outcomes, which supports more responsive titration of therapy.

On the commercial front, supply chain resilience and strategic partnerships between specialty pharmacies, hospital procurement teams, and manufacturers are reshaping distribution. Payers are increasingly focused on outcomes and cost-containment, prompting new contracting models that reward improved functional outcomes and reduced hospitalization. Taken together, these shifts call for adaptive clinical protocols, investment in data-driven monitoring, and collaborative policy engagement to ensure patients receive effective, safe, and accessible pain care.

Assessing the multifaceted operational and procurement consequences of 2025 United States tariff measures on availability and access to cancer pain therapeutics

Policy and trade measures enacted in 2025 have introduced new dynamics that influence procurement, pricing behavior, and supply chain planning for cancer pain therapeutics. Tariff adjustments affecting imported active pharmaceutical ingredients and finished dosage forms have increased the complexity of sourcing decisions for manufacturers and health systems. Many stakeholders have responded by reassessing supplier portfolios and accelerating strategies to diversify manufacturing and raw-material sourcing to mitigate exposure to tariff-driven cost pressures.

For hospital systems and pharmacy networks that manage formularies and procurement, the cumulative effect has been a sharper focus on total cost of care. Procurement teams are negotiating longer-term supply agreements, seeking contractual protections against price volatility, and prioritizing suppliers with vertically integrated capabilities. In parallel, some manufacturers have evaluated onshore or nearshore manufacturing options and strategic partnerships to preserve market access and reduce vulnerability to future trade uncertainties.

These developments also elevate the importance of transparent pricing arrangements and value-based contracting that align payment with measurable clinical outcomes. Clinicians and pharmacy leaders are adapting by emphasizing clinical pathways that demonstrate cost-effectiveness, promoting therapeutic alternatives where clinically appropriate, and engaging with payers to ensure continuity of access for patients with the most significant needs. Ultimately, ongoing policy monitoring and proactive supply chain strategies will be essential to sustaining reliable access to cancer pain medications in a more tariff-sensitive environment.

Detailed segmentation insights that illuminate product positioning, clinical pathway alignment, and distribution differentiation across drug classes, routes, channels, users, and applications

A segmentation-driven analysis reveals differentiated clinical and commercial dynamics across drug classes, routes of administration, distribution channels, end-user settings, and application-specific needs. Based on drug class, the landscape encompasses adjuvant analgesics, local anesthetics, nonsteroidal anti-inflammatory drugs, and opioids. Within adjuvant analgesics, specific subgroups such as anticonvulsants, antidepressants, and corticosteroids address neuropathic and inflammatory components of cancer pain, while opioids are further categorized into natural, semi-synthetic, and synthetic agents that vary in receptor profiles, safety considerations, and regulatory oversight.

Route of administration is another critical axis of differentiation, with oral, parenteral, sublingual, and transdermal options shaping real-world use. Oral therapies are commonly delivered as capsules, solutions, or tablets and remain central to chronic outpatient management, whereas parenteral formulations-delivered intramuscularly, intravenously, or subcutaneously-are essential for acute, procedural, or inpatient care. Sublingual modalities, including films and lozenges, provide rapid onset and convenience for breakthrough pain, and transdermal systems support sustained delivery with adherence advantages in select populations.

Distribution channel nuances inform access and patient experience through hospital pharmacy, online pharmacy, and retail pharmacy pathways, each of which has distinct procurement, dispensing, and stewardship workflows. End-user segmentation spans cancer institutes, home care environments, and hospitals, which differ in clinical expertise, monitoring capabilities, and resource intensity. Finally, application-specific considerations-such as bone metastasis pain, neuropathic pain, and visceral pain-require tailored analgesic strategies and care pathways. Together, these segmentation lenses guide product positioning, clinical guideline development, and targeted stakeholder engagement to meet varied clinical needs and operational realities.

A regional analysis of access models, prescribing practices, and supply chain implications across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics exert powerful influence on access models, therapeutic preferences, and stakeholder priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated delivery systems and a strong specialty pharmacy footprint emphasize rapid adoption of novel delivery platforms and patient support programs, while regulatory focus on opioid safety continues to shape prescribing norms and stewardship initiatives. Contrastively, Europe, Middle East & Africa present a mosaic of payer structures and procurement arrangements, where centralized tendering in some markets coexists with highly localized formularies and differing palliative care infrastructures.

Asia-Pacific markets show marked heterogeneity in infrastructure maturity, with some urban centers adopting advanced multimodal pain management pathways and telemedicine-enabled follow-up, while other areas contend with fragmented access and supply chain constraints. Across all regions, demographic trends and rising survivorship are increasing demand for sustained, patient-centered pain management solutions, but the pathways to access differ based on reimbursement models, local regulatory priorities, and the prevalence of community-based versus hospital-centric care.

Transitioning from regional characteristics to operational implications, stakeholders must tailor clinical education, distribution partnerships, and evidence generation strategies to regional payer expectations and regulatory frameworks. By aligning product dossiers and value narratives with region-specific care models and procurement mechanisms, manufacturers and health systems can better support clinicians and patients within each distinct regional context.

How leading companies are differentiating through R&D, delivery innovation, distribution partnerships, and real-world evidence to address the unmet needs in cancer pain care

Competitive dynamics are evolving as companies pursue differentiated strategies to address clinical complexity and payer demands in cancer pain management. Leading innovators are combining targeted research into non-opioid and adjuvant therapies with investments in novel delivery systems that optimize safety and adherence. In parallel, generic and specialty manufacturers are emphasizing supply reliability and cost-efficiency while expanding services that support adherence, such as patient education and nurse-led titration programs.

Partnerships between pharmaceutical companies and specialty pharmacies or home infusion providers are becoming increasingly important to streamline distribution and support complex dosing regimens. Strategic alliances with technology firms are enabling remote monitoring solutions that feed real-world evidence into value dossiers, strengthening payer negotiations and post-market surveillance. Meanwhile, companies focused on interventional pain technologies and regional anesthetic agents are aligning with clinical centers of excellence to build evidence for procedural pain management protocols.

Across these approaches, successful market participants balance clinical credibility with operational excellence, investing in robust pharmacovigilance, supply chain transparency, and clinician engagement programs. By demonstrating measurable improvements in patient function, adherence, and reduced acute care utilization, companies can strengthen their value proposition to providers and payers while addressing unmet needs in cancer-associated pain management.

Practical and prioritized recommendations for leaders to strengthen supply resilience, advance opioid-sparing therapies, and align commercial models with measurable clinical outcomes

Industry leaders can act decisively to capture clinical trust and commercial advantage by operationalizing several pragmatic recommendations. First, prioritize diversification of supply chains and contingency manufacturing partnerships to reduce exposure to trade and raw-material disruptions while maintaining consistent product availability. At the same time, accelerate development and adoption of non-opioid therapeutics and adjuvant agents that address neuropathic and inflammatory components of cancer pain, thereby supporting opioid-sparing clinical algorithms.

Second, embed digital monitoring and patient-reported outcome tools into care pathways to enable responsive titration, detect adverse events earlier, and generate real-world data that supports value-based contracting. Concurrently, cultivate payer relationships around outcomes measurement by proposing pilot agreements that align reimbursement with functional gains and reductions in acute care utilization. Third, invest in clinician education and stewardship programs that provide practical guidance for multimodal regimens, safe opioid prescribing, and interventional techniques where appropriate.

Finally, tailor commercialization and access plans to the nuances of distribution channels and end-user settings; for example, ensure hospital formularies, home care providers, and specialty pharmacies have the training and materials needed to support complex regimens. Operationalizing these recommendations will require cross-functional collaboration among clinical affairs, supply chain, reimbursement, and commercial teams to translate strategy into measurable improvements in patient care.

A rigorous mixed-methods research framework combining expert interviews, literature synthesis, and real-world evidence with transparency on limitations and ethical safeguards

This analysis synthesizes findings derived from a mixed-methods research approach combining qualitative and quantitative techniques to ensure robust triangulation. Primary research included structured interviews with clinicians, pharmacy leaders, hospital procurement officers, and payer representatives to capture frontline perspectives on clinical needs, formulary decision criteria, and procurement dynamics. These insights were complemented by secondary literature reviews of peer-reviewed clinical guidelines, regulatory announcements, and policy analyses to contextualize evolving standards and stewardship imperatives.

Real-world evidence sources, including anonymized claims and utilization patterns, informed assessments of treatment pathways and administration settings without providing market sizing. The methodology prioritized data quality through cross-validation across independent sources and iterative expert review. Where divergent viewpoints emerged, the analysis explicitly flagged areas of clinical debate and operational uncertainty to aid decision-makers in prioritizing further inquiry.

Limitations of the methodology include variability in regional data availability, evolving regulatory landscapes that may change practice patterns, and heterogeneity in institutional protocols. To mitigate these limitations, the research incorporated sensitivity checks and sought corroboration from multiple stakeholders. Ethical considerations, including patient privacy and responsible use of clinical data, guided the research protocols and stakeholder engagements throughout the study.

A strategic conclusion emphasizing collaboration across clinical, commercial, and policy domains to translate innovation into reliable, patient-centered cancer pain care

In summary, cancer pain management is at a strategic inflection point where clinical innovation, policy pressures, and supply chain realities intersect to redefine how analgesia is delivered and valued. Advances in personalized approaches, non-opioid therapies, and delivery technologies offer meaningful opportunities to improve patient function and safety, but these gains will only be realized if stakeholders align on stewardship, evidence generation, and access models. The evolving tariff and procurement environment further underscore the need for resilient supply strategies and contracting mechanisms that protect continuity of care.

For clinicians, the priority is to integrate multimodal, mechanism-based regimens while leveraging monitoring tools to individualize treatment. For manufacturers and distributors, success depends on demonstrating value through real-world outcomes, securing reliable supply pathways, and engaging payers with pragmatic propositions. For health systems and payers, investments in stewardship, education, and outcome measurement will be critical to achieving sustainable, high-quality pain management for patients with cancer.

Ultimately, a collaborative approach that links clinical excellence with operational rigor and policy engagement will be essential to advance care. Stakeholders who act deliberately-balancing innovation with pragmatic supply and reimbursement strategies-will be best positioned to improve patient outcomes and system-level performance in cancer-related pain management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Pain Management Market, by Drug Class

  • 8.1. Adjuvant Analgesics
    • 8.1.1. Anticonvulsants
    • 8.1.2. Antidepressants
    • 8.1.3. Corticosteroids
  • 8.2. Local Anesthetics
  • 8.3. Nsaids
  • 8.4. Opioids
    • 8.4.1. Natural
    • 8.4.2. Semi-Synthetic
    • 8.4.3. Synthetic

9. Cancer Pain Management Market, by Route Of Administration

  • 9.1. Oral
    • 9.1.1. Capsules
    • 9.1.2. Solutions
    • 9.1.3. Tablets
  • 9.2. Parenteral
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
    • 9.2.3. Subcutaneous
  • 9.3. Sublingual
    • 9.3.1. Films
    • 9.3.2. Lozenges
  • 9.4. Transdermal

10. Cancer Pain Management Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Cancer Pain Management Market, by End User

  • 11.1. Cancer Institutes
  • 11.2. Home Care
  • 11.3. Hospitals

12. Cancer Pain Management Market, by Application

  • 12.1. Bone Metastasis Pain
  • 12.2. Neuropathic Pain
  • 12.3. Visceral Pain

13. Cancer Pain Management Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Pain Management Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Pain Management Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cancer Pain Management Market

17. China Cancer Pain Management Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. Aegis Therapeutics, LLC
  • 18.8. Aptinyx Inc.
  • 18.9. Astellas Pharma Inc.
  • 18.10. Bausch Health Companies Inc.
  • 18.11. Baxter International Inc.
  • 18.12. Bayer AG
  • 18.13. Biogen Inc.
  • 18.14. Boehringer Ingelheim International GmbH
  • 18.15. Eisai Co., Ltd.
  • 18.16. Eli Lilly and Company
  • 18.17. Glaxosmithkline PLC
  • 18.18. Grunenthal Group
  • 18.19. Johnson & Johnson Services, Inc.
  • 18.20. Merck & Co. Inc.
  • 18.21. Novartis AG
  • 18.22. Pfizer Inc.
  • 18.23. Regeneron Pharmaceuticals Inc.
  • 18.24. Sanofi SA
  • 18.25. Scilex Pharmaceuticals
  • 18.26. Teva Pharmaceutical Industries Ltd.
  • 18.27. Trevena Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER PAIN MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER PAIN MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NATURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NATURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NATURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SEMI-SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SEMI-SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SEMI-SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FILMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FILMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FILMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOZENGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOZENGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOZENGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CANCER INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CANCER INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BONE METASTASIS PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BONE METASTASIS PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BONE METASTASIS PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY VISCERAL PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY VISCERAL PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY VISCERAL PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 212. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 213. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 214. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 242. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 245. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 246. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 247. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 252. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 253. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 256. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 257. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 258. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)